Alkermes PLC (ALKS)
|Net Income (ttm)||-62.83M|
|Day's Range||31.65 - 32.38|
|52-Week Range||15.35 - 33.00|
|Price Target||28.13 (-11.2%)|
|Est. Earnings Date||Oct 28, 2021|
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizop... [Read more...]
In 2020, Alkermes's revenue was $1.04 billion, a decrease of -11.29% compared to the previous year's $1.17 billion. Losses were -$110.86 million, -43.62% less than in 2019.Financial Statements
According to 12 analysts, the average rating for Alkermes stock is "Hold." The 12-month stock price forecast is 28.13, which is a decrease of -11.18% from the latest price.
ALKS, BP, and E made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 13, 2021.
Are they stocks to buy near the highs?
Given this backdrop, investors with long-term horizons should remain on the hunt for stocks because timing the market is difficult. Utilizing our Filtered Zacks Rank 5 Stock Screener is a great place to...
DUBLIN, Sept. 22, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Cantor Virtual Global Healthcare Conference on Wednesday, S...
DUBLIN, Sept. 22, 2021 /PRNewswire/ -- A new online survey conducted during the COVID-19 pandemic by The Harris Poll on behalf of Alkermes, Inc., a subsidiary of Alkermes plc (Nasdaq: ALKS), found that ...
Alkermes to Present Two Posters on Investigational Immuno-oncology Candidate, Nemvaleukin Alfa, at the 2021 European ...
DUBLIN, Sept. 13, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced two poster presentations related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered in...
DUBLIN, Sept. 9, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it will begin accepting applications for its annual Alkermes Pathways Research Awards® program on Sept.
DUBLIN, Sept. 2, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Citi 16th Annual BioPharma Virtual Conference on Thursday, S...
Following the recent rally, Alkermes Plc's (NASDAQ:ALKS) shares have exceeded their fair value and the stock looks “expensive on a relative basis,” according to BofA Securities. The Alkermes Analyst: Ja...
The stock price of Alkermes, a biopharmaceutical company focused on neuroscience and oncology, has seen a rise of around 16% over the last twenty-one trading days, and it is up a solid 91% over the last...
Alkermes' (ALKS) portfolio of proprietary products drives growth while its pipeline progress has been impressive. However, heavy dependence on partners for royalty revenues remains a concern.
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock?
The FDA has granted Fast Track designation to Alkermes plc's (NASDAQ: ALKS) nemvaleukin alfa (nemvaleukin) for mucosal melanoma. Nemvaleukin is an investigational engineered interleukin-2 (IL-2) variant...
Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma
DUBLIN, Aug. 2, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to nemvaleukin alfa (nemvaleukin), th...
Following a positive recovery from COVID-impacts, Alkermes (ALKS) beat both earnings and sales estimates in second-quarter 2021. The company also raised its guidance for 2021.
Alkermes (ALKS) delivered earnings and revenue surprises of 150.00% and 9.32%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Shares of Alkermes (NASDAQ:ALKS) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share rose 400.00% over the past year to $0.30, which beat the estimate of $0.12.
DUBLIN, July 28, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the second quarter of 2021 and provided updated financial expectations for full-year 2021. "Alkerme...
DUBLIN, July 23, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the 2021 recipients of grants from the company's signature Alkermes Inspiration Grants® program. Grants were awarded to...
DUBLIN, July 21, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m.
Alkermes Presented New Data Analysis on Healthcare Resource Use Among Veterans With Alcohol Dependence
DUBLIN, June 30, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of new health economics and outcomes research related to healthcare resource use (HRU) among veterans...
Alkermes Announces Former Professional Baseball Player, CC Sabathia, as Spokesperson for Alcohol Dependence Awareness...
DUBLIN, June 22, 2021 /PRNewswire/ -- Alkermes, Inc., a subsidiary of Alkermes plc (Nasdaq: ALKS), today announced former professional baseball player and World Series champion, CC Sabathia, as a spokes...
Biogen isn't the only company whose shares should benefit from a breakthrough drug.
Alkermes Presents New Data on Nemvaleukin Alfa at 2021 American Society of Clinical Oncology Annual Meeting
DUBLIN, June 4, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced new data from its ARTISTRY clinical development program for nemvaleukin alfa (nemvaleukin), Alkermes' novel, investigatio...